2018
Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy
MLEJNEK, Dalibor, Jan KREJČÍ, Petr HUDE, Eva OZÁBALOVÁ, Víta ŽAMPACHOVÁ et. al.Základní údaje
Originální název
Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy
Autoři
MLEJNEK, Dalibor (203 Česká republika, domácí), Jan KREJČÍ (203 Česká republika, garant, domácí), Petr HUDE (203 Česká republika, domácí), Eva OZÁBALOVÁ (203 Česká republika, domácí), Víta ŽAMPACHOVÁ (203 Česká republika, domácí), Radka STEPANOVA (203 Česká republika), Iva SVOBODOVÁ (203 Česká republika, domácí), Tomáš FREIBERGER (203 Česká republika), Eva NEMCOVA (203 Česká republika) a Lenka ŠPINAROVÁ (203 Česká republika, domácí)
Vydání
Archives of Medical Science, Poland, Termedia Publishing House, 2018, 1734-1922
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Polsko
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 2.380
Kód RIV
RIV/00216224:14110/18:00104916
Organizační jednotka
Lékařská fakulta
UT WoS
000448045000005
Klíčová slova anglicky
polymerase chain reaction; myocarditis; dilated cardiomyopathy; endomyocardial biopsy; inflammatory cardiomyopathy
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 11. 2. 2019 15:56, Soňa Böhmová
Anotace
V originále
Introduction: Viral infections are considered the most frequent cause of myocarditis and dilated cardiomyopathy (DCM). Material and methods: We investigated the changes in viral presence and the impact of viral genome persistence in the myocardium on echocardio-graphic parameters, functional status and some laboratory parameters in a 6-month follow-up. Fifty-four patients with recent onset DCM, left ventricular ejection fraction < 40% and biopsy-proven myocarditis (> 14 mononuclear leukocytes/mm(2) and/or > 7 T-lymphocytes/mm(2)) were enrolled. Polymerase chain reaction (PCR) was performed to detect pathogens in the myocardium. Patients were divided according to the administered therapy: standard heart failure medication (46 patients) and immunosuppressive therapy (8 patients). Results: In the standard heart failure medication group viral clearance was observed in 13 patients and viral persistence in 24 patients in the follow-up period. Comparing both groups, there was no statistically significant difference - LVEF improvement of 12.0 +/- 11.4% vs. 18.3 +/- 12.6%, decrease in NYHA class of 0.7 +/- 0.7 vs. 1.0 +/- 0.7, decline in NT-proBNP of 1335 +/- 1933 ng/I vs. 1942 +/- 3242 ng/I and decrease in infiltrating leukocytes of 11.1 +/- 15.8 vs. 6.7 +/- 23.0 cells/mm(2) and T-lymphocytes of 5.8 +/- 15.1 vs. 1.8 +/- 10.9 cells/mm(2) (all p = NS). A decrease in PCR positive patients from 37 to 29 was observed. The number of PVB19 positive PCR findings decreased from 5 to 4 in patients with immunosuppressive therapy. Conclusions: A decrease in the number of positive PCR findings in control endomyocardial biopsy was observed. Viral genome persistence was not associated with worse outcome in short-term follow-up.
Návaznosti
MUNI/A/1443/2014, interní kód MU |
|